Literature DB >> 5631580

Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.

R Pallanza, V Arioli, S Furesz, G Bolzoni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5631580

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


× No keyword cloud information.
  14 in total

1.  Immunosuppressant activity of the ansamycins.

Authors:  J E Kasik; M Monick; J S Thompson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

2.  Experimental chemotherapy of tuberculosis.

Authors:  J Batten
Journal:  Br Med J       Date:  1968-07-13

3.  Editorial: Rifampin in the treatment of tuberculosis.

Authors:  S Grzybowshi
Journal:  Can Med Assoc J       Date:  1974-05-04       Impact factor: 8.262

4.  Stability of rifampin in dimethylsulfoxide.

Authors:  A G Karlson; J A Ulrich
Journal:  Appl Microbiol       Date:  1969-10

Review 5.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

Review 6.  Actions of the rifamycins.

Authors:  W Wehrli; M Staehelin
Journal:  Bacteriol Rev       Date:  1971-09

7.  Susceptibility of Neisseria meningitidis strains from the civilian population to sulfadiazine, penicillin, and rifampin.

Authors:  G L Wiggins; J V McLaughlin; S T Bickham; W L Jones; A Balows
Journal:  Appl Microbiol       Date:  1970-12

8.  [Rifampicin inhibitory titer in wild strains of Mycobacterium and Rifampicin serum concentrations in tuberculous patients].

Authors:  H Hussels; I Schütz
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1969

9.  Mechanism of action of rifampin on Mycobacterium smegmatis.

Authors:  R J White; G C Lancini; L G Silvestri
Journal:  J Bacteriol       Date:  1971-11       Impact factor: 3.490

10.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.